What is known and objective: Beginning in the 1950s, a family of potent opioids was synthesized and developed (fentanyl and analogues). They continue to serve as valuable analgesic agents. But the recent spike and notoriety of their abuse has raised alarm, even calls for tighter control. We review the trajectory of these compounds.
| WHAT IS KNOWN AND OBJECTIVE

Media coverage of "the opioid epidemic" happening in the United
States has become a daily occurrence. Now The New York Times, based on data it recently compiled, estimates that drug overdose deaths in the USA in 2016 most likely exceeded 59 000, the largest annual jump ever recorded in the United States, and greater than traffic mortalities. 1 It is generally agreed that the situation has been made more deadly by an increase in illicitly manufactured fentanyl and similar drugs. For example, the Times reports that in one Ohio county, of the 100 drug overdose deaths recorded over two months, only three people tested positive for heroin; 99 tested positive for fentanyl or an analogue of fentanyl, such as carfentanil. Unfortunately, not all of the reporting on this important issue is scientifically accurate, and the promulgated misinformation can result in misinformed-and even counterproductive-medical, social, regulatory and legal consequences, policies and laws. All stakeholders would benefit from a better understanding of the basic pharmacology of the "fentanyl family" of drugs.
| COMMENTARY
Inaccuracies abound in the coverage of opioid drugs, such as a misunderstanding of the difference between potency and efficacy (typical is "fentanyl is more powerful than heroin") and about basic pharmacology, for example that alfentanil, carfentanil and sufentanil are analogues of fentanyl, and are best understood as part of the same fentanyl "family" (chemical class). This is becoming particularly important with the rise in availability and use of illicit and adulterated products, and in "polysubstance" drug abuse, such as the use of "grey death," a mixture of heroin, fentanyl, carfentanil and U-47700
(a selective kappa-opioid receptor agonist discovered by the Upjohn Co., now a "designer drug").
To be precise, the term "opiates" refers to the naturally occurring compounds morphine and codeine (and thebaine) isolated from the poppy. 2 Compounds that display pharmacologic properties similar to the opiates and have affinity for one of the 7-transmembrane G protein-coupled opioid receptors are "opioids" (thus, the opiates are a subset of opioids). The opioids include the endogenous peptides (eg the endorphins and enkephalins) and legal or illegal substances that bind to these receptors. Modern drug-discovery efforts utilize highthroughput screening assays with cloned human opioid receptors or computational techniques (rational drug design). Prior to the availability of this technology, drug-discovery efforts were driven by screening compounds for pharmacologic activity in animal models. One drug discovered in this way was meperidine (pethidine) in 1939, its analgesic properties recognized despite being originally targeted for another application (anticholinergic). It was meperidine that led to the discovery of fentanyl and its analogues. Lofentanil is similar to carfentanil in potency, but it is longer acting. It is used in certain surgeries. Remifentanil has a rapid onset of action and is short-acting, so finds use as an IV analgesic and adjunct to anaesthesia, allowing rapid recovery following surgery. Sufentanil is more potent than fentanyl and is several 100-fold more potent than morphine; it is used for various surgical applications and postoperative pain management for patients that have become heavily opioid dependent or tolerant because of legitimate long-term use for chronic (cancer) pain, or because of illicit opioid use. It currently is the maximum strength fentanyl analogue approved for use in humans.
Carfentanil is one of the most potent opioids (the most potent opioid used commercially). It is about 100-times more potent than fentanyl, and about 10 000-times more potent than morphine, with activity in humans starting with as little as about 1 μg. It is marketed as a general anaesthetic agent for large animals. Its extreme potency makes it inappropriate for medical use in humans. It has recently received much media attention for its abuse on the "street." Loperamide deserves special mention because its high opioid receptor binding affinity but low passage into the brain makes it useful to treat diarrhoea without producing typical opioid CNS (central nervous system) effects.
Nevertheless, it has been abused by taking very large amounts.
Unfortunately, the same pharmacodynamic and pharmacokinetic properties that make the fentanyl family of drugs effective therapeutic drugs also make them desirable for abuse: CNS action, high potency and rapid brain entry (except for loperamide) that produces a rapid onset of action.
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Non-pharmaceutical fentanyl and analogs are increasingly found in heroin and other drugs in an effort to make these drugs more potent, easier and cheaper to manufacture, and possibly easier to sell. The presence of illicit fentanyl is often not disclosed to the buyer/user.
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According to the Drug Enforcement Administration (DEA), a kilogram of fentanyl powder can be purchased in China for a few thousand dollars and then used to create counterfeit pills, which can be sold for T A B L E 1 Summary of the binding affinity for the mu-opioid receptor (MOR) and half-life of selected members (US-FDA approved drugs) of the fentanyl family and norfentanyl (93.3%) were found as well. Nine samples (30%) tested positive for acetylfentanyl. Only about half of the participants (55%) in this study could identify fentanyl in the heroin they had taken. 16 It is this non-pharmaceutical fentanyl-of which many heroin users are unaware-that is thought to be driving the sudden increase in opioid overdose mortality. 17, 18 In June 2017, the Georgia Bureau of Investigation warned of acrylfentanyl and tetrahydrofuran fentanyl entering the street drug market. 19 Authorities are making efforts to stem the influx of dangerous fentanyl analogs into their communities. In Sarasota, Florida, a man was arrested and charged with murder for selling carfentanil to another man, who died of an overdose in March 2017.
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Drug overdose deaths continue to increase. 21 Although the marked increase in opioid mortality has been associated with the invasion of illicit fentanyl into the USA, 22 the misuse and abuse of opioids exist along a continuum. At one end, there is inappropriate use of an opioid or misuse. A good example of this might be a person who is prescribed an opioid analgesic but who doubles up on a bad day. At the other extreme of the continuum are addicts who are compelled to take opioids, despite the fact that they know they are harmful. Along the continuum are individuals, like young people who experiment with opioids they find a medicine cabinet, and young adults who take opioids recreationally when the opportunity presents itself. 23 Some individuals have been termed "chemical copers" in that they take opioids to help manage stress, control pain or just help them get through the day. 24 Not all individuals who take opioids become addicted, although the reasons why some are more susceptible to addiction than others remain to be elucidated. analogues-or that result from polysubstance overdose involving fentanyl or analogues-to help hospitals manage these types of patients.
Even more concerning is that many hospital personnel have not been formally trained in the special protocols that are required for the management of overdoses that involve the highly potent members of the "fentanyl family," or of polysubstance overdoses involving these drugs.
On the plus side, hospital admission data can provide unique insight and better understanding of the contextual factors that contribute to such cases, and this kind of data might, optimistically, be able to aid in the development of targeted treatment and prevention strategies.
Such a positive outcome can best be accomplished through the establishment of partnerships that promote and enable the sharing of information and integration of approaches among hospitals, healthcare providers, insurers and governmental entities.
| WHAT IS NEW AND CONCLUSION
The recent increase in deaths related to opioid use and abuse has spawned valid and important near-daily coverage in the media. Much of the coverage is accurate and extremely helpful. Unfortunately, some is inaccurate, which leads to confusion and misunderstanding with negative impact on pain patients, healthcare providers, insurers, politicians and the public in general. The recent increase in use of illicit fentanyl and its analogues such as carfentanil either alone or combined with "street" drugs (commonly heroin) has raised concern about these drugs. Their high potency makes overdosing relatively easy with minor variation in purity of the supply, and it makes on-site reversal with naloxone difficult.
Drug abuse and addiction are complex issues, of which the abused drugs are only a part. But psychosocial issues also play a role (such as self-medication, personality disorders, genetics and others). Even the form of the drug makes a large difference in overdose deaths. For example, whereas drug overdose deaths rose dramatically over 1980-2015 in a city in which most heroin was powdered (Philadelphia), there was significantly less increase in a city in which most heroin was black tar (San Francisco).
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The fentanyl "family" of opioids present a particular medical dilemma: the same properties that make them effective and useful analgesics also impart to them desirability for abuse. They have legitimate medical use in human and veterinary practice that is not easily replaced by other drugs. Yet they are currently among the "drugs of choice" that are fuelling the opioid overdose crisis. This leads to a dilemma in this case that might be succinctly characterized as "when good drugs are used for bad purposes." Such a complex issue is best addressed when it is based on the most valid scientific information about all aspects of the problem, including each of the member drugs (legal and illicit) in the fentanyl "family."
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